Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the top gene therapy stocks to buy according to hedge funds. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD), on February 9. 4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg comparator-controlled study of intravitreal 4D-150 in wet AMD, and the primarily endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity at 52 weeks.

David Kirn, M.D., Co-founder, President, and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), stated that the 4D-150 4FRONT-1 Phase 3 trial enrolled in 11 months in a treatment-naïve large market patient population, and is a landmark moment for the company, for wet AMD patients, and for its targeted and locally delivered genetic medicines.

In a separate development, Barclays assumed coverage of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with an Overweight rating on January 27, setting a price target of $33. The firm initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry, telling investors in a research note that it likes the setup for the group in 2026. It further stated that several biotech stocks remain undervalued, and it anticipates “significant tailwinds”, including continued mergers and acquisitions, “strong” underlying fundamentals, and less of a focus on drug pricing.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage genetic medicines company that invents and develops genetic medicines to treat large market diseases in ophthalmology, pulmonology, and cardiology. The company develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, and is currently advancing five clinical-stage and two preclinical product candidates.